IGXT (Mcap $32 M) Submits NDA in March + 3x NDA/ANDA filings in 1H 2013

[Biotechmaster]

This is a real once in a lifetime opportunity ..GLTA

Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by in 2013 because of its very low burn-rate of just $1.2 Mil a year !

IGXT Submits next NDA to the FDA for an Anti-Migraine Versafilm last Week and another 3x More NDA/ANDA filings expected in 1H 2013. This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years .


IGXT has NO DEBT and current Market cap of just $32 M is really a BIG BIG BARGAIN .

My Target is $8-12 within 2 Years .GLTA


Intelgenx (IGXT)

Market Cap : $32 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year

Price : $0.63

Shares Out : 50 M ( 27 M shares are held by Insiders & Institutions)


"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.

March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.



HUGE Prodcut Pipeline



Upcoming Milestones



New Presentation March 2013



Big Buying by Institutions



Analyst Coverage:

IGXT gets 18 month $3.00 Price Target from AEGIS CAPITAL CORP on October 5th, 2012

ide-1-1024.jpg?1349900345

Cleland shares the names of a handful of small companies that could return tenfold or greater multiples to investors.


TLSR: What types of healthcare companies are you looking for? Do you lean toward specialty pharma, where you can monetize more quickly? What are your preferences?

I have at least two investments in this area

[Biotechmaster]

More good News coming out yesterday ..

The Erectile Dysfunction drug was successfully in final Study now the next steps are Partnership and NDA filing which coming within 4 months . NDA acceptance for Anti-Migraine drug coming within 2 weeks .

Another 2 ANDA filings includes the big Par Pharma drug coming before year end . Market Cap of $30 Million is really a Big joke .



Corporate Development Update

Anti-migraine VersaFilm(TM) (rizatriptan)

In March 2013 we announced that, together with our co-development partner RedHill Biopharma Ltd. ("RedHill"), we submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for our anti-migraine oral film product, a novel oral thin-film formulation based on our proprietary VersaFilm(TM) technology containing rizatriptan, the active drug in Merck & Co. ("Merck's") Maxalt-MLT(R) orally disintegrating tablets. According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.

Erectile Dysfunction VersaFilm(TM) (tadalafil)

In February 2013 we successfully completed a pilot bioequivalence study on our erectile dysfunction VersaFilm(TM) product. In a previous study, we had already demonstrated that we are able to formulate a bioequivalent product. In the recently completed study, we showed that we were additionally able to develop a faster formulation with a significantly shorter Tmax which will address the potential need for a faster tadalafil product. We are in active discussions for the licensing of this product.

Development and Commercialization Agreement with Par Pharmaceutical, Inc.

In December 2011 we announced the execution of a co-development and commercialization agreement with Par Pharmaceutical, Inc. ("Par") for a new product utilizing one of our proprietary oral drug delivery platform technologies. This program continues to make progress. For commercial reasons, and in order to protect both Par's and IntelGenx' competitive advantage, the agreement stipulates that all information pertaining to the product, together with financial terms of the agreement, are to remain confidential.

Antihypertensive VersaTab(TM) product

We recently completed a pilot bioequivalence study for our antihypertensive project, INT0001, a generic equivalent to a major cardiovascular product, using our proprietary VersaTab(TM) delivery technology. We continue to make progress with the project and, together with our strategic partner, Dava Pharmaceuticals Inc., are working diligently towards the filing of an ANDA with the FDA.

[Biotechmaster]

New Aegis Capital Update TGT $3 ...




IntelGenx: Looking Towards A Pivotal Year Ahead
May 20, 2013

Forfivo

[Biotechmaster]

Great News out the NDA is accepted . I contacted the CEO via email last week and he confirmed again that we can expect more new Partnerships in this year .

IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product



Look at this Mega Pipeline and you can have this all for a very rdiciulous Market Cap of around $29 Million but not for long thats for sure .

Product Application Status of Development

INT0004/2006 Antidepressant -- US launch in 4Q 2012

INT0008/2007 Migraine -- Submit NDA in March 2013

INT0007/2006 Erectile Dysfunction -- NDA filing later in 2013

INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing later in 2013

INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA filing later in 2013

INT0020/2010 Insomnia -- in Pivotal Study

INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study

INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study

INT0030/2011 Animal health -- in Pivotal Study

INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study